The European Commission has approved the Menarini Group’s Orsedu (elacestrant) as a monotherapy for the treatment of postmenopausal women and men with breast cancer.
Key opinion leaders review the use of antibody-drug conjugates (ADCs) in treating HR+/HER2- metastatic breast cancer, and how they counsel patients before starting them on therapy with an ADC.